NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»01/02/2010 [Industry news]
China Biotech in Review: to 1st Feb 10

A week of China Biotech activity

by: ChinaBio Today, Suzhou Natong BioNanotechnology Ltd. (Nanomed) announced it signed a funding agreement with Softbank’s SB China Venture Capital. In August 2009, Nanomed won the “Most Promising Company” Award in the Medical Device field at the BioBay Investor Forum co-organized by ChinaBio LLC and the Suzhou BioBay life science park. Nanomed’s FMA Intradermal Drug Delivery platform is based on nanoscale MEMS (micro-electro-mechanical) technology. Immediately after closing the funding, Nanomed signed an agreement with an outside company to distribute Nanomed’s Liteclear acne products. Financial details of the funding were not disclosed. For the first time, China exchanges raised more money in annual IPO transactions during 2009 than the US did. Hong Kong, by itself, recorded $31.3 billion worth of IPOs, more than the US total of $26.5 billion. The two mainland PRC exchanges, Shanghai and Shenzhen, were close behind at $24.4 billion. Covance the global CRO, announced construction is underway on a pre-clinical facility near Shanghai, a facility that is currently expected to open late summer 2010 . Joe Herring, Chairman and CEO of Covance, estimated the company will make an investment of between $20 to $25 million to establish the pre-clinical facility, part of which was spent in 2009. Sinovac Biotech upped its secondary stock issue to 10 million shares (from 8.65 million) and priced them at $5.75 each, a 6% discount from last night’s closing quote of $6.11. The company said it expects net proceeds of $53.8 million ($62 million if the underwriters purchase an additional 1.3 million shares for over-allotments). Sinovac’s business focus is on the currently hot vaccine sector. NeoStem said its China subsidiary, Suzhou Erye Pharmaceutical, was granted SFDA approval for omeprazole 20mg capsules. Omeprazole is a proton pump inhibitor prescribed to treat peptic ulcer disease and gastroesophageal reflux disease. The drug is on China\'s National Medical Reimbursement Insurance List, making it eligible for insurance reimbursement. Sinobiopharma reported that its production facility for a capsule form of Perindopril, an ACE inhibitor used to treat high blood pressure, received production approval from the SFDA . The company can now launch the product, which was granted SFDA approval in April 2009. Sinobiopharma will market the product under the name YiTai. It is the first capsule form of Perindopril available in China. China Aoxing Pharma has completed its Phase III trial of Tilidine tablets, a synthetic oral narcotic drug that treats acute and chronic moderate to severe pain, including post-operative and cancer pain. The drug, which is not currently available in China, is a Class III New Medicine that will enjoy at least four years of market exclusivity protection, post-approval. Novo Nordisk reported that Victoza, its once-daily human glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes, was submitted to the SFDA in August of last year. The news came as Novo Nordisk celebrated approval of the product in the US and Japan this week. It has been marketed in Europe since last summer. Bayer Schering Pharma announced it is beginning a Phase IV trial among an Asia Pacific population that combines two blood pressure medications: Adalat, Bayer Schering’s calcium channel blocker (CCB), and valsartan, an angiotensin receptor blocker (ARB) marketed by Novartis under the name Diovan. The goal is to produce lower blood pressure readings than a high dose of valsartan alone.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.